Risk Factors Update Summary
- Accumulated deficit increased from approximately $33 million to $52 million as of December 31, 2023.
- Delay in conducting clinical trials for African HAT indication until the fourth quarter of 2024.
- Cash and cash equivalents decreased from $197 million to $4 million as of December 31, 2023.
- Development phase for suramin production extended to the first quarter of 2024.
- Number of shares outstanding decreased from 1,545,454 to 770,718 as of December 31, 2023.
- Dilution risk increased due to the potential sale of additional shares, impacting existing stockholders.
- Remaining available shares for sale decreased from 549,896 to 102,199 as of December 31, 2023.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1811623&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.